US20230389912A1 - Devices and methods for the treatment of vascular abnormalities - Google Patents
Devices and methods for the treatment of vascular abnormalities Download PDFInfo
- Publication number
- US20230389912A1 US20230389912A1 US18/455,002 US202318455002A US2023389912A1 US 20230389912 A1 US20230389912 A1 US 20230389912A1 US 202318455002 A US202318455002 A US 202318455002A US 2023389912 A1 US2023389912 A1 US 2023389912A1
- Authority
- US
- United States
- Prior art keywords
- occluder
- disc
- laa
- proximal
- distal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12122—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder within the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
- A61B17/12172—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00592—Elastic or resilient implements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00606—Implements H-shaped in cross-section, i.e. with occluders on both sides of the opening
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00623—Introducing or retrieving devices therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00628—T-shaped occluders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
- A61B2017/00632—Occluding a cavity, i.e. closing a blind opening
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00831—Material properties
- A61B2017/00867—Material properties shape memory effect
- A61B2017/00871—Material properties shape memory effect polymeric
Definitions
- the present disclosure relates generally to medical devices that are used in the human body.
- the present disclosure is directed to embodiments of an occlusion device that enables material apposition against tissue walls surrounding a vascular abnormality and facilitates a smooth transition between the tissue and the device.
- the present disclosure is directed to an occlusion device with a disc having an increased depth, giving the disc a more three-dimensional cross-section.
- the embodiments and methods disclosed herein enable improved blood flow along or proximate to the disc after the occlusion device has been placed within the target site.
- An occluder is a medical device used to treat (e.g., occlude) tissue at a target site within the human body, such as an abnormality, a vessel, an organ, an opening, a chamber, a channel, a hole, a cavity, a lumen, or the like.
- an occluder may be used in Left Atrial Appendage (LAA) closures.
- LAAs are common heart defects in which there is a sac in the muscle wall of the left atrium.
- AFib atrial fibrillation
- a blood clot may be formed in the LAA which may become dislodged and enter the blood stream.
- the release of blood clots from the LAA may be significantly reduced, if not eliminated.
- Various techniques have been developed to occlude the LAA. For instance, balloon-like devices have been developed that are configured to be implanted completely within the cavity of the LAA, while surgical techniques have also been developed where the cavity of the LAA is inverted and surgically closed.
- a lobed portion of the device sits in a body of the LAA, and a disc portion is engaged with the opening of the LAA.
- the disc of these known devices is generally a two-dimensional shape, formed from two directly adjacent layers of metal fabric.
- the present disclosure generally relates to medical devices and methods of use thereof, including a disc with increased depth, giving the disc a more three-dimensional cross section which facilitates improved blood flow along or proximate to the disc after the occlusion device has been placed within the target site.
- the present disclosure is directed to a medical device for treating a target site.
- the medical device includes a proximal end and a distal end.
- the proximal end includes a disc and the distal end includes a lobe.
- the disc and the lobe are connected by a connecting member.
- the disc includes a proximal surface, a distal surface, and a central surface.
- the central surface extends between and connects the proximal surface and the distal surface.
- the central surface separates the proximal surface from the distal surface by a predetermined depth distance.
- a delivery system for deploying a medical device to a target site.
- the delivery system includes a medical device and a delivery device.
- the medical device includes a proximal end and a distal end.
- the proximal end includes a disc and the distal end includes a lobe.
- the disc and the lobe are connected by a connecting member.
- the disc includes a proximal surface, a distal surface, and a central surface.
- the central surface extends between and connects the proximal surface and the distal surface.
- the central surface separates the proximal surface from the distal surface by a predetermined depth distance.
- the delivery device includes a delivery catheter, a delivery cable within the delivery catheter and translatable with respect to the delivery catheter, and a coupling member configured to couple the medical device to the delivery cable for facilitating at least one of deployment of the medical device at the target site and subsequent removal of the frame from the medical device.
- a method for occluding a Left Atrial Appendage includes providing a medical device.
- the medical device includes a proximal end and a distal end.
- the proximal end includes a disc and the distal end includes a lobe.
- the disc and the lobe are connected by a connecting member.
- the disc includes a proximal surface, a distal surface, and a central surface.
- the central surface extends between and connects the proximal surface and the distal surface.
- the central surface separates the proximal surface from the distal surface by a predetermined depth distance.
- the method also includes advancing the medical device to the LAA using the delivery system, positioning the medical device relative to the LAA to occlude blood flow, and de-coupling the medical device from the delivery cable to deploy the medical device.
- FIG. 1 is a schematic diagram of blood flow along or proximate to a known medical device, when the medical device is deployed at a target site.
- FIG. 2 is a schematic diagram of a delivery system in accordance with the present disclosure
- FIG. 3 is a schematic diagram of blood flow along or proximate to medical device in accordance with the present disclosure, when the medical device is deployed at a target site;
- FIGS. 4 - 8 illustrate various exemplary embodiments of the medical device, including three-dimensional discs having various shapes and configurations.
- FIG. 9 is a flow diagram of a method of occluding a target site within a patient's vascular system with a device in accordance with the present disclosure.
- the present disclosure relates generally to medical devices that are used in the human body.
- the present disclosure provides medical devices, such as occlusion devices, including a distal lobe and a proximal disc, in which the disc has a defined depth, or a more three-dimensional shape than two-dimensional discs of at least some known medical devices.
- the occlusion devices of the present disclosure facilitate improved and more uniform apposition of the disc against the tissue surrounding the vascular abnormality, which enables a smooth transition between the surrounding tissue and the medical device. Therefore, stagnant blood flow around the medical device or the abnormality may be reduced or eliminated.
- the exemplary embodiment of the medical device is described as treating a target site including a left atrial appendage (LAA), it is understood that the use of the term “target site” is not meant to be limiting, as the medical device may be configured to treat any target site, such as an abnormality, a vessel, an organ, an opening, a chamber, a channel, a hole, a cavity, or the like, located anywhere in the body.
- LAA left atrial appendage
- vascular abnormality as used herein is not meant to be limiting, as the medical device may be configured to bridge or otherwise support a variety of vascular abnormalities.
- the vascular abnormality could be any abnormality that affects the shape of the native lumen, such as an atrial septal defect, an LAA, a lesion, a vessel dissection, or a tumor.
- Embodiments of the medical device may be useful, for example, for occluding an LAA, patent foreman ovalis (PFO), atrial septal defect (ASD), ventricular septal defect (VSD), or patent ductus arteriosus (PDA), as noted above.
- PFO patent foreman ovalis
- ASD atrial septal defect
- VSD ventricular septal defect
- PDA patent ductus arteriosus
- the term “lumen” is also not meant to be limiting, as the vascular abnormality may reside in a variety of locations within the vasculature, such as a vessel, an artery, a vein, a passageway, an organ, a cavity, or the like.
- proximal refers to a part of the medical device or the delivery device that is closest to the operator
- distal refers to a part of the medical device or the delivery device that is farther from the operator at any given time as the medical device is being delivered through the delivery device.
- the terms “deployed” and “implanted” may be used interchangeably herein.
- Some embodiments of the present disclosure provide an improved percutaneous catheter directed intravascular occlusion device for use in the vasculature in patients' bodies, such as blood vessels, channels, lumens, a hole through tissue, cavities, and the like, such as a left atrial appendage. Other physiologic conditions in the body occur where it is also desirous to occlude a vessel or other passageway to prevent blood flow into or therethrough. These device embodiments may be used anywhere in the vasculature where the anatomical conditions are appropriate for the design.
- the medical device may include one or more layers of occlusive material, wherein each layer may be comprised of any material that is configured to substantially preclude or occlude the flow of blood so as to facilitate thrombosis.
- substantially preclude or occlude flow shall mean, functionally, that blood flow may occur for a short time, but that the body's clotting mechanism or protein or other body deposits on the occlusive material results in occlusion or flow stoppage after this initial period.
- At least some conventional or known medical devices 50 used for the occlusion of abnormalities include a disc 52 at a proximal end 54 and a lobe 56 at a distal end 58 thereof.
- Disc 52 is formed from an occlusive material that extends in a flat (e.g., two-dimensional) and planar configuration from a center of medical device 50 to a peripheral edge 60 .
- lobe 56 is positioned within the body of the LAA 62 and provides a layer of occlusion.
- Disc 52 is intended to abut the tissue at an opening 64 of the LAA and provides another layer of occlusion. Additionally, disc 52 prevents lobe 56 from shifting within the body of the LAA 62 .
- disc 52 may recede at least partially into the body of the LAA 62 , which may lead to areas 66 of stagnant flow in the region between opening 64 and the retracted edge 60 of disc 52 , thereby increasing the risk of the patient developing DRT.
- the medical devices of the present disclosure include a disc having a more three-dimensional shape, providing more depth and allowing for greater material apposition against the tissue at the opening to the abnormality while allowing for a smooth transition between the surrounding tissue and the medical device.
- the medical devices of the present disclosure thereby minimize the above-described disadvantages of known medical devices.
- Delivery system 100 includes a delivery device 102 including a catheter 104 and a coupling member 106 configured to couple a distal end of a delivery cable 108 to a medical device 110 for facilitating the deployment of medical device 110 at a target site.
- Medical device 110 is deployed to treat the target site, and, in the example embodiment, is an occlusion device (“occluder”).
- FIG. 3 a schematic diagram of blood flow when medical device 110 according to the present disclosure is utilized for the occlusion of a target site 111 (e.g., an LAA) is shown.
- Medical device 110 includes a proximal end 112 and a distal end 114 , wherein proximal end 112 includes a disc 116 and distal end 114 includes a lobe 118 .
- Disc 116 is connected to lobe 118 by a connecting segment 120 .
- lobe 118 is positioned within the body of the LAA 111 and disc 116 is positioned at an opening 113 of the LAA 111 .
- disc 116 is formed with a three-dimensional shape, or having an appreciable depth, as described further herein, allowing for greater material apposition of disc 116 against tissue or walls 115 of the atrium around the opening 113 to the LAA 111 , while maintaining a smooth transition between the walls 115 of the heart and disc 116 .
- This increased material apposition decreases the risk of stagnant blood flow and ensures normal blood flow in a flow direction 122 proximate to disc 116 (e.g., along a proximal surface 124 thereof).
- FIGS. 4 - 7 illustrate respective exemplary embodiments of disc 116 of medical device 110 .
- an entirety of disc 116 is three-dimensional in shape or has an appreciable depth.
- FIG. 4 is a cross sectional view of disc 116 formed with a rectangular three-dimensional shape
- FIG. 5 is a cross sectional view of disc 116 formed with a half-rounded (or partially rounded) three-dimensional shape
- FIG. 6 is a cross sectional view of disc 116 formed with a fully rounded shape
- FIG. 7 is a cross sectional view of disc 116 formed with a trapezoidal three-dimensional shape.
- disc 116 includes a proximal surface 124 having a first length (or diameter) L 1 , a distal surface 126 having a second length (or diameter) L 2 , and a central surface 128 (also referred to as an edge surface or edge). Central surface 128 extends between and connects proximal surface 124 and distal surface 126 .
- a depth D of disc 116 is defined between proximal surface 124 and distal surface 126 .
- a length of central surface 128 corresponds to or defines depth D.
- depth D is defined consistently along the entirety of disc 116 . In other embodiments, depth D varies along disc 116 . Depth D may be 0.006 to 0.2 inches, more particularly 0.125 to 0.2 inches or 1 mm to 10 mm.
- Proximal surface 124 , distal surface 126 , and central surface 128 define a cavity 130 of disc 116 therebetween.
- disc 116 (and the rest of medical device 110 ) is formed from an occlusive fabric 132 , and cavity 130 is defined between sheets of fabric 132 forming proximal surface 124 and distal surface 126 (which may be each be defined by a single layer or a double layer of fabric 132 ). That is, depth D represents a depth distance defined between these surfaces 124 , 126 and by which surface 124 , 126 are separated.
- first length L 1 (or diameter) of proximal surface 124 may be approximately equal to second length L 2 (or diameter) of distal surface 126 . As shown in FIGS. 5 and 7 , first length L 1 of proximal surface 124 may be greater than second length L 2 of distal surface 126 .
- central surface 128 extends linearly between proximal surface 124 and distal surface 126 (see, e.g., FIGS. 4 and 7 ).
- Central surface 128 may adjoin proximal surface 124 at an angle A 1 .
- Angle A 1 may be approximately equal to a 90 degree angle or may be less than 90 degrees.
- Central surface 128 may adjoin distal surface 126 at an angle A 2 .
- Angle A 2 may be greater than or equal to about 90 degrees.
- Central surface 128 may alternatively adjoin proximal surface 124 and/or distal surface 126 with an angular or arcuate (e.g., curved) connection (see, e.g., FIGS. 5 and 6 ). It is also contemplated that central surface 128 may be curved between proximal surface 124 and distal surface 126 (see, e.g., FIGS. 5 and 6 ). Central surface 128 may have a radius of curvature. The radius of curvature may be in a range between 0.003 to 0.1 inches, more particularly 0.0625 to 0.1 inches or 2 mm to 10 mm. The radius of curvature may vary to ensure proper occlusive function and/or positioning of disc 116 within opening 113 , while maintaining normal blood flow along or proximate to disc 116 .
- FIG. 8 illustrates another embodiment of disc 116 of medical device 110 , in which portions of disc 116 are three-dimensional.
- Proximal surface 124 includes a proximal peripheral portion 134 .
- Distal surface 126 includes a distal peripheral portion 136 .
- Central surface 128 extends between and connects proximal peripheral portion 134 and distal peripheral portion 136 .
- proximal peripheral portion 134 and/or distal peripheral portion 136 extends in a proximal longitudinal direction.
- cavity 130 is defined along the periphery of disc 116 , as an annular cavity 130 . That is, proximal surface 124 and distal surface 126 are spaced apart only along the periphery of disc 116 .
- the depth distance D defined between proximal surface 124 and distal surface 126 at peripheral portions 134 , 136 thereof, provides a three-dimensional shape to the peripheral edges of disc 116 .
- a central portion 140 of proximal surface 124 , radially inward of peripheral portion 134 is directly adjacent to a central portion 142 of distal surface 126 , radially inward of peripheral portion 136 (e.g., no cavity 130 is defined between surfaces 124 , 126 in this central portion).
- medical device 110 is formed from a shape-memory material.
- shape memory material that may be used is Nitinol.
- Nitinol alloys are highly elastic and are said to be “superelastic,” or “pseudoelastic.” This elasticity may allow medical device 110 to be resilient and return to a preset, expanded configuration for deployment following passage in a distorted form through delivery catheter 104 .
- Further examples of materials and manufacturing methods for medical devices with shape memory properties are provided in U.S. Publication No. 2007/0265656 titled “Multi-layer Braided Structures for Occluding Vascular Defects” and filed on Jun. 21, 2007, which is incorporated by reference herein in its entirety.
- medical device may be formed from various materials other than Nitinol that have elastic properties, such as stainless steel, trade named alloys such as Elgiloy®, or Hastalloy, Phynox®, MP35N, CoCrMo alloys, metal, polymers, or a mixture of metal(s) and polymer(s).
- Suitable polymers may include PET (DacronTM), polyester, polypropylene, polyethylene, HDPE, Pebax, nylon, polyurethane, silicone, PTFE, polyolefins and ePTFE.
- the medical device may comprise any material that has the desired elastic properties to ensure that the device may be deployed, function as an occluder, and be recaptured in a manner disclosed within this application.
- disc 116 is shaped as desired by heat-setting fabric 132 over a mandrel having a complementary shape. Additionally or alternatively, disc 116 may include a frame therein, where the frame has the desired final shape of disc 116 . Fabric 132 may be coupled to this frame to form disc 116 .
- method 900 includes providing 902 a medical device.
- the medical device includes a proximal end and a distal end, wherein the proximal end comprises a disc and the distal end comprises a lobe, wherein the disc and lobe are connected by a connecting member, wherein the disc comprises a proximal surface, a distal surface, and a central surface extending between and connecting the proximal surface and distal surface, wherein the central surface separates the proximal surface from the distal surface by a predetermined depth distance.
- Method 900 also includes advancing 904 the medical device to the LAA using a delivery system including a catheter and a delivery cable, positioning 906 the medical device relative to the LAA to occlude blood flow to and from the LAA, and de-coupling 908 the medical device from the delivery cable to deploy the medical device
- Method 900 may include additional, alternative, and/or fewer steps, including those described herein.
- positioning 906 the medical device relative to the LAA includes placing the lobe of the medical device within the body of the LAA and the disc outside of the LAA to abut the adjacent wall surrounding the opening of the LAA.
- de-coupling 908 the medical device from the delivery cable includes transitioning the medical device from the constricted configuration adopted for delivery from a catheter to the preset expanded configuration.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Surgical Instruments (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 17/391,666, filed Aug. 2, 2021, which claims the benefit of priority to U.S. Provisional Patent Application No. 63/060,221, filed Aug. 3, 2020, the entire contents of both of which are hereby incorporated by reference herein.
- The present disclosure relates generally to medical devices that are used in the human body. In particular, the present disclosure is directed to embodiments of an occlusion device that enables material apposition against tissue walls surrounding a vascular abnormality and facilitates a smooth transition between the tissue and the device. More specifically, the present disclosure is directed to an occlusion device with a disc having an increased depth, giving the disc a more three-dimensional cross-section. The embodiments and methods disclosed herein enable improved blood flow along or proximate to the disc after the occlusion device has been placed within the target site.
- An occluder is a medical device used to treat (e.g., occlude) tissue at a target site within the human body, such as an abnormality, a vessel, an organ, an opening, a chamber, a channel, a hole, a cavity, a lumen, or the like. For example, an occluder may be used in Left Atrial Appendage (LAA) closures. LAAs are common heart defects in which there is a sac in the muscle wall of the left atrium. When a patient experiences atrial fibrillation (AFib), a blood clot may be formed in the LAA which may become dislodged and enter the blood stream. By occluding the LAA, the release of blood clots from the LAA may be significantly reduced, if not eliminated. Various techniques have been developed to occlude the LAA. For instance, balloon-like devices have been developed that are configured to be implanted completely within the cavity of the LAA, while surgical techniques have also been developed where the cavity of the LAA is inverted and surgically closed.
- In the case of some known medical devices, a lobed portion of the device sits in a body of the LAA, and a disc portion is engaged with the opening of the LAA. The disc of these known devices is generally a two-dimensional shape, formed from two directly adjacent layers of metal fabric. With the diverse anatomy of LAAs, the implantation of a medical device designed to occlude the LAA may not result in optimal implantation, and the two-dimensional disc of the above described medical devices may potentially slip at least partially into the opening of the LAA, which may lead to areas of stagnant blood flow within the patient's vascular system. The presence of stagnant blood flow may increase the risk of a patient developing device related thrombosis (DRT), which may lead to further medical complications.
- It would be advantageous to provide an improved occlusion device that reduces the risk of DRT by minimizing stagnant blood flow proximate to the deployed medical device.
- The present disclosure generally relates to medical devices and methods of use thereof, including a disc with increased depth, giving the disc a more three-dimensional cross section which facilitates improved blood flow along or proximate to the disc after the occlusion device has been placed within the target site.
- In one embodiment, the present disclosure is directed to a medical device for treating a target site. The medical device includes a proximal end and a distal end. The proximal end includes a disc and the distal end includes a lobe. The disc and the lobe are connected by a connecting member. The disc includes a proximal surface, a distal surface, and a central surface. The central surface extends between and connects the proximal surface and the distal surface. The central surface separates the proximal surface from the distal surface by a predetermined depth distance.
- In another embodiment, a delivery system for deploying a medical device to a target site is provided. The delivery system includes a medical device and a delivery device. The medical device includes a proximal end and a distal end. The proximal end includes a disc and the distal end includes a lobe. The disc and the lobe are connected by a connecting member. The disc includes a proximal surface, a distal surface, and a central surface. The central surface extends between and connects the proximal surface and the distal surface. The central surface separates the proximal surface from the distal surface by a predetermined depth distance. The delivery device includes a delivery catheter, a delivery cable within the delivery catheter and translatable with respect to the delivery catheter, and a coupling member configured to couple the medical device to the delivery cable for facilitating at least one of deployment of the medical device at the target site and subsequent removal of the frame from the medical device.
- In a further embodiment, a method for occluding a Left Atrial Appendage is provided. The method includes providing a medical device. The medical device includes a proximal end and a distal end. The proximal end includes a disc and the distal end includes a lobe. The disc and the lobe are connected by a connecting member. The disc includes a proximal surface, a distal surface, and a central surface. The central surface extends between and connects the proximal surface and the distal surface. The central surface separates the proximal surface from the distal surface by a predetermined depth distance. The method also includes advancing the medical device to the LAA using the delivery system, positioning the medical device relative to the LAA to occlude blood flow, and de-coupling the medical device from the delivery cable to deploy the medical device.
-
FIG. 1 is a schematic diagram of blood flow along or proximate to a known medical device, when the medical device is deployed at a target site. -
FIG. 2 is a schematic diagram of a delivery system in accordance with the present disclosure; -
FIG. 3 is a schematic diagram of blood flow along or proximate to medical device in accordance with the present disclosure, when the medical device is deployed at a target site; -
FIGS. 4-8 illustrate various exemplary embodiments of the medical device, including three-dimensional discs having various shapes and configurations; and -
FIG. 9 is a flow diagram of a method of occluding a target site within a patient's vascular system with a device in accordance with the present disclosure. - Corresponding reference characters indicate corresponding parts throughout the several views of the drawings. It is understood that that Figures are not necessarily to scale.
- The present disclosure relates generally to medical devices that are used in the human body. Specifically, the present disclosure provides medical devices, such as occlusion devices, including a distal lobe and a proximal disc, in which the disc has a defined depth, or a more three-dimensional shape than two-dimensional discs of at least some known medical devices.
- Accordingly, the occlusion devices of the present disclosure facilitate improved and more uniform apposition of the disc against the tissue surrounding the vascular abnormality, which enables a smooth transition between the surrounding tissue and the medical device. Therefore, stagnant blood flow around the medical device or the abnormality may be reduced or eliminated.
- The disclosed embodiments may lead to more consistent and improved patient outcomes. It is contemplated, however, that the described features and methods of the present disclosure as described herein may be incorporated into any number of systems as would be appreciated by one of ordinary skill in the art based on the disclosure herein.
- Although the exemplary embodiment of the medical device is described as treating a target site including a left atrial appendage (LAA), it is understood that the use of the term “target site” is not meant to be limiting, as the medical device may be configured to treat any target site, such as an abnormality, a vessel, an organ, an opening, a chamber, a channel, a hole, a cavity, or the like, located anywhere in the body. The term “vascular abnormality,” as used herein is not meant to be limiting, as the medical device may be configured to bridge or otherwise support a variety of vascular abnormalities. For example, the vascular abnormality could be any abnormality that affects the shape of the native lumen, such as an atrial septal defect, an LAA, a lesion, a vessel dissection, or a tumor. Embodiments of the medical device may be useful, for example, for occluding an LAA, patent foreman ovalis (PFO), atrial septal defect (ASD), ventricular septal defect (VSD), or patent ductus arteriosus (PDA), as noted above. Furthermore, the term “lumen” is also not meant to be limiting, as the vascular abnormality may reside in a variety of locations within the vasculature, such as a vessel, an artery, a vein, a passageway, an organ, a cavity, or the like. As used herein, the term “proximal” refers to a part of the medical device or the delivery device that is closest to the operator, and the term “distal” refers to a part of the medical device or the delivery device that is farther from the operator at any given time as the medical device is being delivered through the delivery device. In addition, the terms “deployed” and “implanted” may be used interchangeably herein.
- Some embodiments of the present disclosure provide an improved percutaneous catheter directed intravascular occlusion device for use in the vasculature in patients' bodies, such as blood vessels, channels, lumens, a hole through tissue, cavities, and the like, such as a left atrial appendage. Other physiologic conditions in the body occur where it is also desirous to occlude a vessel or other passageway to prevent blood flow into or therethrough. These device embodiments may be used anywhere in the vasculature where the anatomical conditions are appropriate for the design.
- The medical device may include one or more layers of occlusive material, wherein each layer may be comprised of any material that is configured to substantially preclude or occlude the flow of blood so as to facilitate thrombosis. As used herein, “substantially preclude or occlude flow” shall mean, functionally, that blood flow may occur for a short time, but that the body's clotting mechanism or protein or other body deposits on the occlusive material results in occlusion or flow stoppage after this initial period.
- The present disclosure now will be described more fully hereinafter with reference to the accompanying drawings, in which some, but not all embodiments of the disclosure are shown. Indeed, this disclosure may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. Like numbers refer to like elements throughout.
- As shown in
FIG. 1 , at least some conventional or knownmedical devices 50 used for the occlusion of abnormalities include adisc 52 at aproximal end 54 and alobe 56 at adistal end 58 thereof.Disc 52 is formed from an occlusive material that extends in a flat (e.g., two-dimensional) and planar configuration from a center ofmedical device 50 to aperipheral edge 60. - When known
medical device 50 is deployed at a target site 62 (e.g., a left atrial appendage (LAA)),lobe 56 is positioned within the body of theLAA 62 and provides a layer of occlusion.Disc 52 is intended to abut the tissue at anopening 64 of the LAA and provides another layer of occlusion. Additionally,disc 52 preventslobe 56 from shifting within the body of theLAA 62. Whendisc 52 has a two-dimensional configuration,disc 52 may recede at least partially into the body of theLAA 62, which may lead toareas 66 of stagnant flow in the region betweenopening 64 and the retractededge 60 ofdisc 52, thereby increasing the risk of the patient developing DRT. - The medical devices of the present disclosure include a disc having a more three-dimensional shape, providing more depth and allowing for greater material apposition against the tissue at the opening to the abnormality while allowing for a smooth transition between the surrounding tissue and the medical device. The medical devices of the present disclosure thereby minimize the above-described disadvantages of known medical devices.
- Turning now to
FIG. 2 , a schematic diagram of a delivery system 100 is shown. Delivery system 100 includes adelivery device 102 including acatheter 104 and acoupling member 106 configured to couple a distal end of adelivery cable 108 to amedical device 110 for facilitating the deployment ofmedical device 110 at a target site.Medical device 110 is deployed to treat the target site, and, in the example embodiment, is an occlusion device (“occluder”). - Turning now to
FIG. 3 , a schematic diagram of blood flow whenmedical device 110 according to the present disclosure is utilized for the occlusion of a target site 111 (e.g., an LAA) is shown.Medical device 110 includes aproximal end 112 and adistal end 114, whereinproximal end 112 includes adisc 116 anddistal end 114 includes alobe 118.Disc 116 is connected to lobe 118 by a connectingsegment 120. Whendevice 110 is deployed at theLAA 111,lobe 118 is positioned within the body of theLAA 111 anddisc 116 is positioned at anopening 113 of theLAA 111. In the exemplary embodiment,disc 116 is formed with a three-dimensional shape, or having an appreciable depth, as described further herein, allowing for greater material apposition ofdisc 116 against tissue orwalls 115 of the atrium around theopening 113 to theLAA 111, while maintaining a smooth transition between thewalls 115 of the heart anddisc 116. This increased material apposition decreases the risk of stagnant blood flow and ensures normal blood flow in aflow direction 122 proximate to disc 116 (e.g., along aproximal surface 124 thereof). -
FIGS. 4-7 illustrate respective exemplary embodiments ofdisc 116 ofmedical device 110. In these embodiments, an entirety ofdisc 116 is three-dimensional in shape or has an appreciable depth. Specifically,FIG. 4 is a cross sectional view ofdisc 116 formed with a rectangular three-dimensional shape,FIG. 5 is a cross sectional view ofdisc 116 formed with a half-rounded (or partially rounded) three-dimensional shape,FIG. 6 is a cross sectional view ofdisc 116 formed with a fully rounded shape, andFIG. 7 is a cross sectional view ofdisc 116 formed with a trapezoidal three-dimensional shape. - As shown in
FIGS. 4-7 ,disc 116 includes aproximal surface 124 having a first length (or diameter) L1, adistal surface 126 having a second length (or diameter) L2, and a central surface 128 (also referred to as an edge surface or edge).Central surface 128 extends between and connectsproximal surface 124 anddistal surface 126. A depth D ofdisc 116 is defined betweenproximal surface 124 anddistal surface 126. In some embodiments, a length ofcentral surface 128 corresponds to or defines depth D. In some embodiments, such as the embodiment ofdisc 116 shown inFIG. 4 , depth D is defined consistently along the entirety ofdisc 116. In other embodiments, depth D varies alongdisc 116. Depth D may be 0.006 to 0.2 inches, more particularly 0.125 to 0.2 inches or 1 mm to 10 mm. -
Proximal surface 124,distal surface 126, andcentral surface 128 define acavity 130 ofdisc 116 therebetween. In the exemplary embodiment, disc 116 (and the rest of medical device 110) is formed from anocclusive fabric 132, andcavity 130 is defined between sheets offabric 132 formingproximal surface 124 and distal surface 126 (which may be each be defined by a single layer or a double layer of fabric 132). That is, depth D represents a depth distance defined between these 124, 126 and by whichsurfaces 124, 126 are separated.surface - As shown in
FIGS. 4 and 6 , first length L1 (or diameter) ofproximal surface 124 may be approximately equal to second length L2 (or diameter) ofdistal surface 126. As shown inFIGS. 5 and 7 , first length L1 ofproximal surface 124 may be greater than second length L2 ofdistal surface 126. - In some embodiments,
central surface 128 extends linearly betweenproximal surface 124 and distal surface 126 (see, e.g.,FIGS. 4 and 7 ).Central surface 128 may adjoinproximal surface 124 at an angle A1. Angle A1 may be approximately equal to a 90 degree angle or may be less than 90 degrees.Central surface 128 may adjoindistal surface 126 at an angle A2. Angle A2 may be greater than or equal to about 90 degrees. -
Central surface 128 may alternatively adjoinproximal surface 124 and/ordistal surface 126 with an angular or arcuate (e.g., curved) connection (see, e.g.,FIGS. 5 and 6 ). It is also contemplated thatcentral surface 128 may be curved betweenproximal surface 124 and distal surface 126 (see, e.g.,FIGS. 5 and 6 ).Central surface 128 may have a radius of curvature. The radius of curvature may be in a range between 0.003 to 0.1 inches, more particularly 0.0625 to 0.1 inches or 2 mm to 10 mm. The radius of curvature may vary to ensure proper occlusive function and/or positioning ofdisc 116 withinopening 113, while maintaining normal blood flow along or proximate todisc 116. -
FIG. 8 illustrates another embodiment ofdisc 116 ofmedical device 110, in which portions ofdisc 116 are three-dimensional.Proximal surface 124 includes a proximalperipheral portion 134.Distal surface 126 includes a distalperipheral portion 136.Central surface 128 extends between and connects proximalperipheral portion 134 and distalperipheral portion 136. In some embodiments, proximalperipheral portion 134 and/or distalperipheral portion 136 extends in a proximal longitudinal direction. - In the embodiment of
FIG. 8 ,cavity 130 is defined along the periphery ofdisc 116, as anannular cavity 130. That is,proximal surface 124 anddistal surface 126 are spaced apart only along the periphery ofdisc 116. The depth distance D, defined betweenproximal surface 124 anddistal surface 126 at 134, 136 thereof, provides a three-dimensional shape to the peripheral edges ofperipheral portions disc 116. Acentral portion 140 ofproximal surface 124, radially inward ofperipheral portion 134, is directly adjacent to acentral portion 142 ofdistal surface 126, radially inward of peripheral portion 136 (e.g., nocavity 130 is defined between 124, 126 in this central portion).surfaces - In one embodiment,
medical device 110 is formed from a shape-memory material. One particular shape memory material that may be used is Nitinol. Nitinol alloys are highly elastic and are said to be “superelastic,” or “pseudoelastic.” This elasticity may allowmedical device 110 to be resilient and return to a preset, expanded configuration for deployment following passage in a distorted form throughdelivery catheter 104. Further examples of materials and manufacturing methods for medical devices with shape memory properties are provided in U.S. Publication No. 2007/0265656 titled “Multi-layer Braided Structures for Occluding Vascular Defects” and filed on Jun. 21, 2007, which is incorporated by reference herein in its entirety. - It is also understood that medical device may be formed from various materials other than Nitinol that have elastic properties, such as stainless steel, trade named alloys such as Elgiloy®, or Hastalloy, Phynox®, MP35N, CoCrMo alloys, metal, polymers, or a mixture of metal(s) and polymer(s). Suitable polymers may include PET (Dacron™), polyester, polypropylene, polyethylene, HDPE, Pebax, nylon, polyurethane, silicone, PTFE, polyolefins and ePTFE. Additionally, it is contemplated that the medical device may comprise any material that has the desired elastic properties to ensure that the device may be deployed, function as an occluder, and be recaptured in a manner disclosed within this application.
- In some embodiments,
disc 116 is shaped as desired by heat-settingfabric 132 over a mandrel having a complementary shape. Additionally or alternatively,disc 116 may include a frame therein, where the frame has the desired final shape ofdisc 116.Fabric 132 may be coupled to this frame to formdisc 116. - Turning now to
FIG. 9 , a flow diagram of anexemplary method 900 of usingmedical device 110 to occlude an LAA in a patient is shown. In the exemplary embodiment,method 900 includes providing 902 a medical device. As described herein, the medical device includes a proximal end and a distal end, wherein the proximal end comprises a disc and the distal end comprises a lobe, wherein the disc and lobe are connected by a connecting member, wherein the disc comprises a proximal surface, a distal surface, and a central surface extending between and connecting the proximal surface and distal surface, wherein the central surface separates the proximal surface from the distal surface by a predetermined depth distance. -
Method 900 also includes advancing 904 the medical device to the LAA using a delivery system including a catheter and a delivery cable, positioning 906 the medical device relative to the LAA to occlude blood flow to and from the LAA, andde-coupling 908 the medical device from the delivery cable to deploy the medical device -
Method 900 may include additional, alternative, and/or fewer steps, including those described herein. For example, in some embodiments, positioning 906 the medical device relative to the LAA includes placing the lobe of the medical device within the body of the LAA and the disc outside of the LAA to abut the adjacent wall surrounding the opening of the LAA. - Additionally, de-coupling 908 the medical device from the delivery cable includes transitioning the medical device from the constricted configuration adopted for delivery from a catheter to the preset expanded configuration.
- While embodiments of the present disclosure have been described, it should be understood that various changes, adaptations and modifications may be made therein without departing from the spirit of the disclosure and the scope of the appended claims. Further, all directional references (e.g., upper, lower, upward, downward, left, right, leftward, rightward, top, bottom, above, below, vertical, horizontal, clockwise, and counterclockwise) are only used for identification purposes to aid the reader's understanding of the present disclosure, and do not create limitations, particularly as to the position, orientation, or use of the disclosure. It is intended that all matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative only and not limiting. Changes in detail or structure may be made without departing from the spirit of the disclosure as defined in the appended claims.
- Many modifications and other embodiments of the disclosure set forth herein will come to mind to one skilled in the art to which this disclosure pertains having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the disclosure is not to be limited to the specific embodiments described and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
- Any patent, publication, or other disclosure material, in whole or in part, that is said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated materials does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.
Claims (20)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18/455,002 US20230389912A1 (en) | 2020-08-03 | 2023-08-24 | Devices and methods for the treatment of vascular abnormalities |
| US19/323,394 US20260007396A1 (en) | 2020-08-03 | 2025-09-09 | Devices and methods for the treatment of vascular abnormalities |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060221P | 2020-08-03 | 2020-08-03 | |
| US17/391,666 US11771410B2 (en) | 2020-08-03 | 2021-08-02 | Devices and methods for the treatment of vascular abnormalities |
| US18/455,002 US20230389912A1 (en) | 2020-08-03 | 2023-08-24 | Devices and methods for the treatment of vascular abnormalities |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/391,666 Continuation US11771410B2 (en) | 2020-08-03 | 2021-08-02 | Devices and methods for the treatment of vascular abnormalities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US19/323,394 Division US20260007396A1 (en) | 2020-08-03 | 2025-09-09 | Devices and methods for the treatment of vascular abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20230389912A1 true US20230389912A1 (en) | 2023-12-07 |
Family
ID=77168068
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/391,666 Active 2041-10-29 US11771410B2 (en) | 2020-08-03 | 2021-08-02 | Devices and methods for the treatment of vascular abnormalities |
| US18/455,002 Abandoned US20230389912A1 (en) | 2020-08-03 | 2023-08-24 | Devices and methods for the treatment of vascular abnormalities |
| US19/323,394 Pending US20260007396A1 (en) | 2020-08-03 | 2025-09-09 | Devices and methods for the treatment of vascular abnormalities |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/391,666 Active 2041-10-29 US11771410B2 (en) | 2020-08-03 | 2021-08-02 | Devices and methods for the treatment of vascular abnormalities |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US19/323,394 Pending US20260007396A1 (en) | 2020-08-03 | 2025-09-09 | Devices and methods for the treatment of vascular abnormalities |
Country Status (2)
| Country | Link |
|---|---|
| US (3) | US11771410B2 (en) |
| EP (2) | EP4420618A3 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11771410B2 (en) * | 2020-08-03 | 2023-10-03 | St. Jude Medical, Cardiology Division, Inc. | Devices and methods for the treatment of vascular abnormalities |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939078A (en) * | 1974-04-19 | 1976-02-17 | Johnson & Johnson | Extracorporeal filter |
| US5944738A (en) * | 1998-02-06 | 1999-08-31 | Aga Medical Corporation | Percutaneous catheter directed constricting occlusion device |
| US20060064159A1 (en) * | 2003-10-08 | 2006-03-23 | Porter Christopher H | Device and method for vascular access |
| US20070208376A1 (en) * | 2006-03-03 | 2007-09-06 | Jian Meng | Occlusion device with internal fastener |
| US20120172927A1 (en) * | 2010-11-12 | 2012-07-05 | Campbell Benjamin D | Left atrial appendage occlusive devices |
| US20130006343A1 (en) * | 2011-06-30 | 2013-01-03 | Cvdevices, Llc | Devices, systems, and methods for inverting and closing the left atrial appendage |
| US20140142612A1 (en) * | 2011-06-01 | 2014-05-22 | Lifetech Scientific (Shenzhen) Co., Ltd. | Left Atrial Appendage Occluder |
| US8961556B2 (en) * | 2007-07-12 | 2015-02-24 | Aga Medical Corporation | Percutaneous catheter directed intravascular occlusion devices |
| US20190008495A1 (en) * | 2015-12-31 | 2019-01-10 | Lifetech Scientific (Shenzhen) Co., Ltd. | Left atrial appendage occluder |
| US11771410B2 (en) * | 2020-08-03 | 2023-10-03 | St. Jude Medical, Cardiology Division, Inc. | Devices and methods for the treatment of vascular abnormalities |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8777974B2 (en) | 2004-03-19 | 2014-07-15 | Aga Medical Corporation | Multi-layer braided structures for occluding vascular defects |
| EP1982655B2 (en) * | 2007-04-16 | 2022-12-07 | Occlutech Holding AG | Occluder to seal an atrial appendage and method of manufacture thereof |
| US9259225B2 (en) * | 2008-02-19 | 2016-02-16 | St. Jude Medical, Cardiology Division, Inc. | Medical devices for treating a target site and associated method |
| US8764787B2 (en) * | 2011-06-17 | 2014-07-01 | Aga Medical Corporation | Occlusion device and associated deployment method |
| JP2017517320A (en) * | 2014-06-11 | 2017-06-29 | オクルテック ホールディング エージー | Left atrial appendage occluder |
| CN104856741B (en) * | 2015-06-15 | 2017-11-10 | 同济大学附属第十人民医院 | One kind is through conduit left atrial appendage occlusion system |
| EP3322353B1 (en) * | 2015-07-13 | 2023-01-11 | Marvel Medical Technologies LLC | Device for left atrial appendage closure |
| JP6937327B2 (en) * | 2016-03-17 | 2021-09-22 | スワミナサン ジャヤラマン | Anatomical blockage |
| US11259788B2 (en) * | 2016-09-26 | 2022-03-01 | St. Jude Medical, Cardiology Division, Inc. | Percutaneous catheter directed intravascular occlusion devices with retractable stabilizing wires |
| CN108938034B (en) | 2017-05-23 | 2025-09-05 | 杭州德诺电生理医疗科技有限公司 | Left atrial appendage occluder with improved sealing effect and preparation method thereof |
| WO2020123386A1 (en) * | 2018-12-10 | 2020-06-18 | Boston Scientific Scimed, Inc. | Left atrial appendage implant with sealing balloon |
-
2021
- 2021-08-02 US US17/391,666 patent/US11771410B2/en active Active
- 2021-08-02 EP EP24189206.6A patent/EP4420618A3/en active Pending
- 2021-08-02 EP EP21189037.1A patent/EP3949876B1/en active Active
-
2023
- 2023-08-24 US US18/455,002 patent/US20230389912A1/en not_active Abandoned
-
2025
- 2025-09-09 US US19/323,394 patent/US20260007396A1/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939078A (en) * | 1974-04-19 | 1976-02-17 | Johnson & Johnson | Extracorporeal filter |
| US5944738A (en) * | 1998-02-06 | 1999-08-31 | Aga Medical Corporation | Percutaneous catheter directed constricting occlusion device |
| US20060064159A1 (en) * | 2003-10-08 | 2006-03-23 | Porter Christopher H | Device and method for vascular access |
| US20070208376A1 (en) * | 2006-03-03 | 2007-09-06 | Jian Meng | Occlusion device with internal fastener |
| US8961556B2 (en) * | 2007-07-12 | 2015-02-24 | Aga Medical Corporation | Percutaneous catheter directed intravascular occlusion devices |
| US20120172927A1 (en) * | 2010-11-12 | 2012-07-05 | Campbell Benjamin D | Left atrial appendage occlusive devices |
| US20140142612A1 (en) * | 2011-06-01 | 2014-05-22 | Lifetech Scientific (Shenzhen) Co., Ltd. | Left Atrial Appendage Occluder |
| US20130006343A1 (en) * | 2011-06-30 | 2013-01-03 | Cvdevices, Llc | Devices, systems, and methods for inverting and closing the left atrial appendage |
| US20190008495A1 (en) * | 2015-12-31 | 2019-01-10 | Lifetech Scientific (Shenzhen) Co., Ltd. | Left atrial appendage occluder |
| US11771410B2 (en) * | 2020-08-03 | 2023-10-03 | St. Jude Medical, Cardiology Division, Inc. | Devices and methods for the treatment of vascular abnormalities |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4420618A3 (en) | 2024-09-25 |
| EP3949876A1 (en) | 2022-02-09 |
| EP3949876B1 (en) | 2024-09-18 |
| US20260007396A1 (en) | 2026-01-08 |
| US20220031295A1 (en) | 2022-02-03 |
| US11771410B2 (en) | 2023-10-03 |
| EP4420618A2 (en) | 2024-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12364468B2 (en) | Occluder with access passage and closure thereof | |
| US20240065840A1 (en) | Flow regulating device in the heart | |
| US12433599B2 (en) | Frame and patch design for occluder with access passage | |
| JP6042889B2 (en) | Cardiac occlusion device | |
| US20240423598A1 (en) | Devices and methods for occlusion of vascular system abnormalities | |
| WO2014130535A1 (en) | Heart occlusion devices | |
| KR20110127737A (en) | Cardiac occlusion device | |
| CN103857341A (en) | Heart occlusion devices | |
| US20260007396A1 (en) | Devices and methods for the treatment of vascular abnormalities | |
| US20240115249A1 (en) | Biomaterial occluder delivery mechanism | |
| US20230404559A1 (en) | Occluder medical device | |
| EP4104772B1 (en) | Devices for the treatment of vascular abnormalities | |
| US20250295414A1 (en) | Left Atrial Appendage Occluder Hook Placement | |
| US20250345065A1 (en) | Left Atrial Appendage Occluder with Pulmonary Ridge Disc Coverage | |
| US20220240911A1 (en) | Devices and methods for the treatment of vascular abnormalities | |
| US20220257224A1 (en) | Occluder medical device | |
| CN121400898A (en) | Frame and patch design of occluders with intervention channels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ST. JUDE MEDICAL, CARDIOLOGY DIVISION, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORIN, KRISTEN;SPRINGER, TREVOR;SAMARAY, ANDREY;REEL/FRAME:064693/0031 Effective date: 20210715 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION COUNTED, NOT YET MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |